CY1106692T1 - Παραγωγα του αλοξενοϋλ-κυκλοπροπαν-1-καρβοξυλικου οξεος - Google Patents
Παραγωγα του αλοξενοϋλ-κυκλοπροπαν-1-καρβοξυλικου οξεοςInfo
- Publication number
- CY1106692T1 CY1106692T1 CY20071100873T CY071100873T CY1106692T1 CY 1106692 T1 CY1106692 T1 CY 1106692T1 CY 20071100873 T CY20071100873 T CY 20071100873T CY 071100873 T CY071100873 T CY 071100873T CY 1106692 T1 CY1106692 T1 CY 1106692T1
- Authority
- CY
- Cyprus
- Prior art keywords
- branched
- linear
- alkyl
- alloxenoyl
- cyclopropane
- Prior art date
Links
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 2
- 102100037652 Kynurenine 3-monooxygenase Human genes 0.000 abstract 2
- 108010033242 Kynurenine 3-monooxygenase Proteins 0.000 abstract 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 229960005070 ascorbic acid Drugs 0.000 abstract 1
- 235000010323 ascorbic acid Nutrition 0.000 abstract 1
- 239000011668 ascorbic acid Substances 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229930195712 glutamate Natural products 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- -1 phenoxy, benzyloxy Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Οι ενώσεις του τύπου (I), όπου το R είναι υδροξύλιο, γραμμικό ή διακλαδισμένο C1-C6 αλκοξύλιο, φαινοξύλιο, βενζυλοξύλιο, μια ομάδα -N(R1R2), όπου το R1 είναι υδρογόνο, γραμμικό ή διακλαδισμένο C1-C4 αλκύλιο, βενζύλιο, φαινύλιο και το R2 είναι υδρογόνο ή γραμμικό ή διακλαδισμένο C1-C4 αλκύλιο, ή το R είναι ένα γλυκοσιδικό υπόλειμμα ή ένα πρωτοταγές υπόλειμμα αλκοξύλιου από ασκορβικό οξύ, προαιρετικά με μια ή περισσότερες υδροξυλικές ομάδες, αλκυλιωμένες ή ακυλιωμένες με μια γραμμική ή διακλαδισμένη C1-C4 αλκυλική ή ακυλική ομάδα· το Χ είναι ένα άτομο αλογόνου και το n 1 ή 2 είναι μακράς διαρκείας αναστολείς της 3-μονοοξυγενάσης κυνουρενίνης (ΚΜΟ) και ισχυροί αναστολείς της απελευθέρωσης γλουταμινικού (GLU).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02026597A EP1424333A1 (en) | 2002-11-28 | 2002-11-28 | Halothenoyl-cyclopropane-1-carboxylic acid derivatives |
| EP03811772A EP1565451B1 (en) | 2002-11-28 | 2003-11-25 | Halothienoyl-cyclopropane-1-carboxylic acid derivatives |
| PCT/EP2003/013244 WO2004048361A1 (en) | 2002-11-28 | 2003-11-25 | Halothenoyl-cyclopropane-1-carboxylic acid derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1106692T1 true CY1106692T1 (el) | 2012-05-23 |
Family
ID=32241303
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20071100873T CY1106692T1 (el) | 2002-11-28 | 2007-07-02 | Παραγωγα του αλοξενοϋλ-κυκλοπροπαν-1-καρβοξυλικου οξεος |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20060116329A1 (el) |
| EP (2) | EP1424333A1 (el) |
| JP (1) | JP4522864B2 (el) |
| AT (1) | ATE361921T1 (el) |
| AU (1) | AU2003296596B2 (el) |
| CA (1) | CA2507597A1 (el) |
| CY (1) | CY1106692T1 (el) |
| DE (1) | DE60313798T2 (el) |
| DK (1) | DK1565451T3 (el) |
| ES (1) | ES2286509T3 (el) |
| PT (1) | PT1565451E (el) |
| SI (1) | SI1565451T1 (el) |
| WO (1) | WO2004048361A1 (el) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1475088A1 (en) * | 2003-05-05 | 2004-11-10 | Newron Pharmaceuticals S.p.A. | Use of kynurenine-3-hydroxylase inhibitors for the preparation of medicaments for the treatment of l-dopa induced movement disorders, dyskinesias, drug addiction, pain and cataract |
| GB2402940A (en) * | 2004-08-19 | 2004-12-22 | Pfizer Ltd | Biomarkers of inflammation and/or macrophage activation |
| WO2006120104A1 (en) * | 2005-04-11 | 2006-11-16 | Probiodrug Ag | Inhibitors of prolyl endopeptidase |
| WO2012175513A1 (en) | 2011-06-20 | 2012-12-27 | Bayer Intellectual Property Gmbh | Thienylpyri(mi)dinylpyrazole |
| US9822058B2 (en) * | 2012-04-05 | 2017-11-21 | Chdi Foundation, Inc. | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| EP3049077A4 (en) * | 2013-09-26 | 2017-02-15 | CHDI Foundation, Inc. | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| US9938252B2 (en) | 2013-09-26 | 2018-04-10 | Chdi Foundation, Inc. | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| GB201322512D0 (en) | 2013-12-19 | 2014-02-05 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201508864D0 (en) | 2015-05-22 | 2015-07-01 | Glaxosmithkline Ip Dev Ltd | Compounds |
| GB201508857D0 (en) | 2015-05-22 | 2015-07-01 | Glaxosmithkline Ip Dev Ltd | Compounds |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1278435B (de) * | 1965-01-19 | 1968-09-26 | Merck Ag E | Verfahren zur Herstellung von 1, 2-disubstituierten Cyclopropanderivaten |
| US4022903A (en) * | 1975-06-05 | 1977-05-10 | Abbott Laboratories | α-Thienyl and α-substituted thienyl, phenyl and substituted phenyl cyclopropylomethanols useful as biodegradable insecticides and mollusicides |
| US6274590B1 (en) * | 1993-01-15 | 2001-08-14 | G. D. Searle & Co. | Method of treating skin related conditions |
| WO1998018760A1 (fr) * | 1996-10-30 | 1998-05-07 | Shionogi & Co., Ltd. | Inhibiteur de la liberation du glutamate et nouveaux composes |
| GB9705031D0 (en) * | 1997-03-11 | 1997-04-30 | Pharmacia & Upjohn Spa | 2-substituted benzoyl-cycloalkyl-1-carboxylic acid derivatives |
-
2002
- 2002-11-28 EP EP02026597A patent/EP1424333A1/en not_active Withdrawn
-
2003
- 2003-11-25 AT AT03811772T patent/ATE361921T1/de not_active IP Right Cessation
- 2003-11-25 PT PT03811772T patent/PT1565451E/pt unknown
- 2003-11-25 JP JP2004554463A patent/JP4522864B2/ja not_active Expired - Fee Related
- 2003-11-25 AU AU2003296596A patent/AU2003296596B2/en not_active Ceased
- 2003-11-25 DE DE60313798T patent/DE60313798T2/de not_active Expired - Lifetime
- 2003-11-25 EP EP03811772A patent/EP1565451B1/en not_active Expired - Lifetime
- 2003-11-25 DK DK03811772T patent/DK1565451T3/da active
- 2003-11-25 US US10/536,307 patent/US20060116329A1/en not_active Abandoned
- 2003-11-25 CA CA002507597A patent/CA2507597A1/en not_active Abandoned
- 2003-11-25 WO PCT/EP2003/013244 patent/WO2004048361A1/en active IP Right Grant
- 2003-11-25 SI SI200330828T patent/SI1565451T1/sl unknown
- 2003-11-25 ES ES03811772T patent/ES2286509T3/es not_active Expired - Lifetime
-
2007
- 2007-07-02 CY CY20071100873T patent/CY1106692T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP4522864B2 (ja) | 2010-08-11 |
| CA2507597A1 (en) | 2004-06-10 |
| DK1565451T3 (da) | 2007-09-10 |
| DE60313798T2 (de) | 2008-01-24 |
| US20060116329A1 (en) | 2006-06-01 |
| AU2003296596B2 (en) | 2010-03-04 |
| EP1565451B1 (en) | 2007-05-09 |
| JP2006509753A (ja) | 2006-03-23 |
| SI1565451T1 (sl) | 2007-08-31 |
| ATE361921T1 (de) | 2007-06-15 |
| AU2003296596A1 (en) | 2004-06-18 |
| EP1565451A1 (en) | 2005-08-24 |
| EP1424333A1 (en) | 2004-06-02 |
| ES2286509T3 (es) | 2007-12-01 |
| PT1565451E (pt) | 2007-08-03 |
| WO2004048361A1 (en) | 2004-06-10 |
| DE60313798D1 (en) | 2007-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1106692T1 (el) | Παραγωγα του αλοξενοϋλ-κυκλοπροπαν-1-καρβοξυλικου οξεος | |
| ES2188016T3 (es) | Derivaqdo de benzamidoxima, productos intermedios y procedimiento para su obtencion y su empleo como fungicidas. | |
| HN1997000027A (es) | Derivados de 6-fenil piridil - 2 amina | |
| EP1490371A4 (en) | TRICYCLIC COMPOUNDS BASED ON THIOPENE AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS | |
| DK0931788T3 (da) | Metalloproteasehæmmere | |
| NO20052887L (no) | Pyridazinonderivater som GSK-3Beta inhibitorer. | |
| TW200612920A (en) | Novel imidazolidine derivatives | |
| DK0669968T3 (da) | Aniliner som mærkningsmidler til mineralolier | |
| HUP0104218A2 (hu) | Új szubsztituált fenil-ciklohexil vegyületekből származó észterek | |
| ES2171040T3 (es) | Derivados de esteres hidroxiaceticos y su utilizacion como intermediarios de sintesis. | |
| HUP0402235A2 (hu) | 4,4-Difluor-1,2,3,4-tetrahidro-5H-1-benzazepin-származékok és ezek sói és ezeket tartalmazó gyógyszerkészítmények | |
| CO5720994A2 (es) | Derivados sustituidos del pirrol | |
| AR010080A1 (es) | Derivados de 1,2,3,4-tetrahidronaftaleno | |
| PA8478301A1 (es) | Derivados ftalacinicos inhibidores de la fosfodiesterasa 4 | |
| MX9304579A (es) | Derivados de 4-aza-5alfa-androstan-3-ona 17beta-substituidos, fluorados, proceso para su preparaciony composicion farmaceutica que los comprende. | |
| NO20050871L (no) | 6-amino-1H-indazol- og 4-aminobenzofuranforbindelser som fosfodiesterase 4-inhibitorer | |
| ES2177275T3 (es) | Derivados de oxadiazolina y su uso como insecticidas. | |
| CY1105786T1 (el) | Εκδοχα φλαβονων η διαδικασια παρασκευης τους, η εφαρμογη τους ως φαρμακα | |
| NO20052994L (no) | Nye fosforamidderivater. | |
| HUP0400772A2 (hu) | Eljárás piperazinszármazékok mezilátjainak előállítására és ezen vegyületek | |
| PT1102781E (pt) | Novos co-factores para metiltransferases | |
| DK1450750T3 (da) | Derivater af 2-amoni-4-pyridiylmethylthiazolin og anvendelse deraf som inhibitorer af inducerbar NO-syntase | |
| ES2189736T3 (es) | Derivados de la benzamida y medicamentos que los contienen. | |
| AR008228A1 (es) | Derivados aromaticos sustituidos con un radical de ribosa, su procedimiento de preparacion, compuestos intermediarios para su exclusivo uso en dicho procedimiento, medicamentos y composiciones farmaceuticas. | |
| CO5540381A2 (es) | Derivados de imidazotriacinonas y su uso contra procesos inflamatorios y/o enfermedades inmunitarias |